191 related articles for article (PubMed ID: 30611005)
21. Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy.
Sunkaraneni S; Passarell JA; Ludwig EA; Fiedler-Kelly J; Pitner JK; Grinnell TA; Blum D
Clin Pharmacol; 2017; 9():65-72. PubMed ID: 28721105
[TBL] [Abstract][Full Text] [Related]
22. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.
Shorvon SD; Trinka E; Steinhoff BJ; Holtkamp M; Villanueva V; Peltola J; Ben-Menachem E
J Neurol; 2017 Mar; 264(3):421-431. PubMed ID: 28101651
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.
Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P;
Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures.
Sunkaraneni S; Ludwig EA; Passarell JA; Blum D; Grinnell T; Fiedler-Kelly J
J Clin Pharmacol; 2018 Jul; 58(7):927-938. PubMed ID: 29528499
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
26. Levels of anger in epilepsy patients treated with eslicarbazepine acetate.
Toledo M; Mazuela G; Mauri JA; Rodriguez-Osorio X; Gómez-Eguilaz M; Castro-Vilanova D; Rodriguez-Uranga J; Santamarina E
Acta Neurol Scand; 2019 Jul; 140(1):48-55. PubMed ID: 30953593
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of eslicarbazepine acetate monotherapy for focal-onset seizures: A multicenter audit.
Giráldez BG; Garamendi-Ruiz I; Zurita J; García A; Querol R; Campos D; Cabeza-Alvarez C; Serrano P; López-González FJ; Molins A; Serratosa JM
Acta Neurol Scand; 2019 Dec; 140(6):422-428. PubMed ID: 31498422
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial.
Kirkham F; Auvin S; Moreira J; Gama H; Falcão AC; Rocha JF; Soares-da-Silva P
Epilepsy Behav; 2020 Apr; 105():106962. PubMed ID: 32151803
[TBL] [Abstract][Full Text] [Related]
29. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.
Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P
Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333
[TBL] [Abstract][Full Text] [Related]
30. [Exalief as a newer antiepileptic drug for adjunctive therapy of refractory partial-onset seizures].
Ermolenko NA; Buchneva IA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):129-34. PubMed ID: 25629136
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.
Gil-Nagel A; Elger C; Ben-Menachem E; Halász P; Lopes-Lima J; Gabbai AA; Nunes T; Falcão A; Almeida L; da-Silva PS
Epilepsia; 2013 Jan; 54(1):98-107. PubMed ID: 22882018
[TBL] [Abstract][Full Text] [Related]
32. Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-Esli.
Holtkamp M; Delanty N; Sales F; Serratosa J; McMurray R; Villanueva V
Acta Neurol Scand; 2019 Jan; 139(1):49-63. PubMed ID: 30176048
[TBL] [Abstract][Full Text] [Related]
33. Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs.
Mintzer S; Wechsler RT; Rogin JB; Gidal BE; Schwab M; Ben-Menachem E; Carreño M; da Silva PS; Moreira J; Li Y; Blum D; Grinnell T
Epilepsy Res; 2018 Mar; 141():83-89. PubMed ID: 29499473
[TBL] [Abstract][Full Text] [Related]
34. Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures.
Shirley M; Dhillon S
Drugs; 2016 Apr; 76(6):707-17. PubMed ID: 27055527
[TBL] [Abstract][Full Text] [Related]
35. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
[TBL] [Abstract][Full Text] [Related]
36. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.
Falcão A; Fuseau E; Nunes T; Almeida L; Soares-da-Silva P
CNS Drugs; 2012 Jan; 26(1):79-91. PubMed ID: 22171585
[TBL] [Abstract][Full Text] [Related]
38. EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.
Villanueva V; Bermejo P; Montoya J; Toledo M; Gómez-Ibáñez A; Garcés M; Vilella L; López-González FJ; Rodriguez-Osorio X; Campos D; Martínez P; Giner P; Zurita J; Rodríguez-Uranga J; Ojeda J; Mauri JA; Camacho JL; Ruiz-Giménez J; Poza JJ; Massot-Tarrús A; Galiano ML; Bonet M
Acta Neurol Scand; 2017 Sep; 136(3):254-264. PubMed ID: 27935017
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
Pazdera L; Sperling MR; Harvey JH; Sam MC; Strom LA; Blum D; Grinnell T; Cheng H
Epilepsia; 2018 Mar; 59(3):704-714. PubMed ID: 29450890
[TBL] [Abstract][Full Text] [Related]
40. Seizure reduction and quality of life improvements in people with epilepsy.
Birbeck GL; Hays RD; Cui X; Vickrey BG
Epilepsia; 2002 May; 43(5):535-8. PubMed ID: 12027916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
